Ananda’s mission is to be a leading provider of cannabinoid medicines for the treatment of complex, chronic inflammatory pain conditions. Ananda is listed on the AQSE Growth Market in London.
Ananda has a medical cannabis cultivation facility in the UK and develops pharmaceutical cannabinoid oils through its subsidiary MRX Medical.
MRX’s cannabinoid oils are manufactured in the UK to EU GMP requirements, consistent from batch to batch and suitable for use in clinical trials. MRX’s first formulation, MRX1, is being used in two Phase II randomised controlled trials to investigate the efficacy of cannabidiol in treating chemotherapy induced peripheral neuropathy and endometriosis.